J&J Ruling Removes FDA Warnings From Plaintiff Playbook

Law360, New York (March 21, 2014, 8:13 PM EDT) -- The Arkansas Supreme Court's surprise reversal of a landmark $1.2 billion judgment against Johnson & Johnson on Thursday held that U.S. Food and Drug Administration warning letters are often too prejudicial to use as evidence against pharmaceutical companies, eliminating a powerful tool that plaintiffs have relied on to sway juries.

The state’s highest court ruled that a 2003 warning letter the FDA sent J&J unit Janssen Pharmaceuticals Inc., in which the agency accused Janssen of misleading doctors about the diabetes risks of its antipsychotic drug Risperdal,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.